(12/14, Gever) reports, "The anticoagulant drug rivaroxaban (Xarelto)
has turned out better in everyday clinical practice for preventing
venous thromboembolism (VTE) in surgery patients than expected from the
drug's registration studies," according to an abstract presented at the
American Society of Hematology. Phase III VTE prevention trial results
showed that "VTE incidence following major orthopedic surgery fell to
2.4% after rivaroxaban was introduced as the primary prophylactic
treatment, compared with 5.5% with
fondaparinux (Arixtra) and 3.9% with low-molecular-weight heparin" and
there were less major bleeding complications. In addition, "this
retrospective study in a nonselected patient population suggests that
prophylaxis with rivaroxaban is superior to both fondaparinux and LMWH
in preventing symptomatic VTE complications, and appeared to be safer
with regard to severe bleeding complications."
No comments:
Post a Comment